Oncology Central

Vinflunine for the treatment of metastatic transitional cell carcinoma: recent evidence from clinical trials and observational studies


The microtubule inhibitor vinflunine is currently the only cytotoxic drug approved in Europe for the treatment of patients with metastatic transitional cell carcinoma who failed first-line platinum-based chemotherapy. Indeed, the only Phase III trial ever conducted in this setting demonstrated a benefit in progression-free and overall survival for patients receiving vinflunine plus best supportive care compared with best supportive care alone.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.